Skip to main content

MicroRNA-183 Inhibits A375 Human Melanoma Cell Migration and Invasion

In the following study, researchers test the effect of microRNA-183 (miR-183) on A375 melanoma cells. Lentiviral transfection was used to construct an A375 cell line with stable miR-183 over-expression or knockdown. Additionally, reverse transcription-quantitative polymerase chain reaction was used to measure the change of miR-183 expression in A375 cells, and a scratch and Transwell assay was used to determine its effects on A375 cell migration. Results show that miR-183 expression inhibits A375 migration and invasiveness. This effect is supported by the fact that Ezrin and MMP-9, two known promoters of melanoma metastasis, are revealed to be negatively regulated by miR-183. Therefore, miR-183 may inhibit A375 melanoma cell migration by targeting and inhibiting Ezrin and MMP-9 expression. This study may ultimately contribute novel insights to the development of anti-metastasis gene therapy. [LINK]
An A375 Transfection Reagent is commercially available from Altogen Biosystems, which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found here. 

Comments

Post a Comment

Popular posts from this blog

Bufotalin Induces A375 Cell Cycle Arrest and Apoptosis

Bufotalin, an active component of Venenum bufonis, has long been used as an anti-tumor drug in China and has proven anti-tumor effects in cancer types. In the following study, researchers use MTT and colony formation assays to analyze the effects of bufotalin on A375 melanoma cells. Results show that bufotalin induces A375 cell cycle arrest at the G2/M phase by up-regulating and down-regulating specific protein expressions. Furthermore, bufotalin up-regulates apoptosis-related proteins, in turn inducing A375 cell apoptosis. These results indicate that bufotalin may prove effective in melanoma treatment. [ LINK ] An  A375 Transfection Reagent  is commercially available from  Altogen Biosystems , which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found  here .
Post a Comment
Read more

About the A375 Cell Line

A375 cells have been used as test organisms that also produce paracrine factors for prolonged culture of mesenchymal stromal cells (MSCs). Melanoma is the most lethal formal of skin cancer and is responsible for more than 75% of skin cancer-related deaths. The A375 cell line is relevant to melanoma studies, and it was originally obtained from a 54-year-old female. A375 cells are epithelial-like with adherent properties, hypotriploid, and have a modal number of 62 chromosomes. The cells produce large amounts of amelanotic melanomas in xenografts of NIH swiss mice treated with anti-thymocyte serum. A375 cells are suitable for transfection applications, especially those that deal with oncogenetic factors that are tied to melanomas. For the A375 transfection reagent , visit the Altogen Biosystems website.
Post a Comment
Read more

Combined IL-24/OSM Adenoviral-mediated Gene Therapy Enhances Suppression of A375 Melanoma

In this study, researchers test the anti-tumor effects of combined IL-24/OSM adenoviral-mediated tumor suppressor gene co-transfer in A375 cells. Interleukin-24 (IL-24) is a cytokine-tumor suppressor that exhibits anti-tumor properties. Oncostatin M (OSM) inhibits the proliferation of various solid tumor cell lines. Researchers combined IL-24 and OSM to form a bicistronic adenovirus and tested its effect on A375 cells in vivo and in vitro . Results indicate that IL-24/OSM reduces certain protein expressions in A375 cell cycles and this activity is closely associated with the activation of an apoptotic pathway and inhibition of tumor angiogenesis. Therefore, combining two or more tumor suppressors may lead to a new strategy of treating melanoma. [ LINK ] An  A375 Transfection Reagent  is commercially available from  Altogen Biosystems , which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found  here ...
Post a Comment
Read more